CureVac N.V. logo

CureVac N.V.

CureVac N.V., a clinical-stage biopharmaceutical company, focuses on developing various transformative medicines based on messenger ribonucleic acid (mRNA). Its product candidates are also developed for prophylactic vaccines, cancer immunotherapy and other therapeutic areas. The company's lead product candidate is CVnCoV that is in Phase I human clinical trials to protect against coronaviruses, including the SARS-CoV-2 virus. It also develops additional prophylactic vaccine antibiotics, including CV301, which is in Phase II clinical trials for treating non-small cell lung cancer and cervical cancer; CV9202 in preclinical stage for treating melanoma and prostate cancer; and CV8102 preclinical stage for treating breast and pancreatic cancers.

The company's mRNA therapeutics have demonstrated their potential to treat cancers through the triggering of intracellular immune responses. CureVac N.V. operates in the United States, Germany, and internationally. The company was formerly known as Curevac GmbH and changed its name to CureVac N.V. in December 2016.

Latest events on Quartr

Previous Events for CureVac N.V.




United States of America

About the company

Investor Relations page

Dig deeper into the fundamentals using Quartr - Investor relations

  • Skip straight to the Q&A session
  • Receive notifications about new events
  • Connect the financial calender on your phone
  • Figure out why the stock is up or down
  • Read the transcripts or scroll the deck
  • Access earnings or press releases
Android play link
App store link
Quartr app screenshot